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The glycolytic enzyme pyruvate kinase (PK) generates ATP from ADP through 21 
substrate-level phosphorylation powered by the conversion of phosphoenolpyruvate to 22 
pyruvate. In contrast to other bacteria, Enterobacteriaceae, such as pathogenic yersiniae, 23 
harbour two pyruvate kinases encoded by pykA and pykF. The individual roles of these 24 
isoenzymes are poorly understood. In an attempt to make the Yersinia enterocolitica pyruvate 25 
kinases PykA and PykF amenable to structural and functional characterization, we produced 26 
them untagged in E. coli and purified them to near homogeneity through a combination of ion 27 
exchange and size exclusion chromatography, yielding more than 180 milligram per litre of 28 
batch culture. The solution structure of PykA and PykF was analysed through small angle X-29 
ray scattering which revealed the formation of PykA and PykF tetramers and confirmed the 30 









● High-level expression and purification of Yersinia enterocolitica pyruvate kinase     40 
    isoenzymes PykA and PykF 41 
● Efficient two-step purification without any affinity tag 42 





Pyruvate kinase (PK) catalyses the last step in glycolysis enabling substrate-level 47 
phosphorylation to form ATP from ADP on the expenditure of phosphoenolpyruvate which is 48 
converted to pyruvate. Within the last years, research on PK enzymes experienced a 49 
significant boost as it became more and more evident that these enzymes play a crucial role in 50 
tumor biology and therefore represent potential drug targets [1]. Furthermore, interest in 51 
bacterial and parasites’ PK enzymes has developed in search of potential drug target 52 
molecules [2-5]. While four PK isoenzymes are known in mammalians, bacteria typically 53 
harbour a single PK enzyme. However, a few bacteria harbour two PK isoenzymes, especially 54 
members of the Enterobacteriaceae such as E. coli, Salmonella and Yersinia. The type I PK 55 
(PykF) of E. coli is characterised as an enzyme that is allosterically activated by FBP, whereas 56 
type II PK (PykA) is not [6, 7]. The two PK types are phylogenetically distant and share a 57 
sequence identity of only 37% in E. coli and of 39% identity in Y. enterocolitica. While PykF 58 
crystal structures are available and show the tetrameric organisation typical of PK enzymes 59 
[8, 9], structural data on PykA homologues are missing. In activity assays, PykF significantly 60 
surpasses PykA activity under all conditions tested [6, 10, 11] leaving open the question of 61 
why these bacteria need two isoenzymes. In E. coli, the deletion of both pyk genes increases 62 
expression and activity of phosphoenolpyruvate carboxylase (PEPC), a fact that indicates the 63 
rerouting of carbon fluxes via PEPC [12]. Similarly, deletion of the pykF gene alone also 64 
stimulated PEPC expression and activity, which suggested a low-level residual PK activity 65 
mediated by PykA [11]. 66 
Recently, our attention was drawn to pyruvate kinases of pathogenic Yersinia as we 67 
identified an interrelationship between their type three secretion system (T3SS) and central 68 
carbon metabolism [13]. The Yersinia T3SS is supposed to form a molecular microinjection 69 
device dedicated to the manipulation of host cells by injection of effector proteins [14]. 70 
 4 
Regulatory components of the Yersinia enterocolitica T3SS, YscM1 and YscM2, were found 71 
to physically interact with Yersinia PEPC, and metabolic flux analyses furthermore suggested 72 
a role of PK in this regulatory network of virulence and metabolic functions [13].  73 
Given that many of the few bacteria harbouring two PK isoenzymes are pathogens, 74 
understanding their particular roles may contribute to our understanding of virulence. 75 
The PK isoenzymes PykA and PykF of Yersinia have not been studied to date. Here, 76 
we report on the highly efficient large-scale recombinant production of both isoenzymes, 77 
making them amenable to structural and functional characterisation. 78 
 79 
Materials and methods 80 
 81 
Construction of expression plasmids  82 
 83 
Pyruvate kinase encoding genes pykA and pykF of Y. enterocolitica WA-314 were 84 
amplified by PCR as follows and inserted into IPTG-inducible expression vector pWS 85 
[15]. To amplify pykA by PCR the following oligonucleotides were used: pykA_NdeI_for (5’-86 
AATGACATATGTCCAGACGGCTTAGAAGGAC-3’) and pykA_BglII_rev (5’-87 
CACATAGATCTTCATTCAACACGCAGAATGCGGC-3’), while for amplification of pykF 88 
the primers pykF_NdeI_for (5’-89 
AATGACATATGAAAAAGACTAAAATTGTTTGTACTATCG-3’) and pykF_SalI_rev (5’-90 
CACAGGTCGACTTATAAAACGTGCACGGAAGAGGTATTGG-3’) were 91 
used. Underlined letters in the primer sequences indicate restriction enzyme recognition sites 92 
introduced for subsequent ligation into expression vector pWS. The resulting plasmids (pWS-93 
pykA and pWS-pykF) were confirmed by DNA sequencing and were transformed into 94 
expression strain E. coli BL21 (DE3) pLysS. 95 
 96 
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Protein expression and purification 97 
 98 
Overnight cultures of E. coli BL21 (DE3) pLysS pWS-pykA 99 
and E. coli BL21 (DE3) pLysS pWS-pykF, respectively, were grown in 2YT medium (16 g/L 100 
tryptone, 5 g/L yeast extract, 5 g/L NaCl) at 37°C, diluted 1:50 into 400 mL of 2YT and 101 
cultured in a 2L-flask at 37°C and 150 rpm until OD600nm reached a value of 0.6. Expression 102 
was induced by addition of 0.1 mM IPTG and cultures were incubated for 5 hours at 27°C. 103 
Cells were harvested by centrifugation and pellets frozen at -80°C. Cell pellets were 104 
solubilised at 4°C in 10 mM Tris pH 8.5, 50 mM KCl, 5 mM DTT at a ratio of 7 mL of buffer 105 
per gram of cell paste. The solubilization buffer was supplemented with Complete Protease 106 
Inhibitor Cocktail (Roche Diagnostics GmbH). Cells were lysed applying three passages 107 
through an EmulsiFlex-C3 homogeniser (Avestin). Lysates were cleared by centrifugation at 108 
20.000 g for 20 min and subsequent passage through 0.2 µm sterile filters (Sartorius, 109 
Germany).    110 
Ion exchange chromatography: A HiPrep 16/10 Q XL column (GE Healthcare) was 111 
equilibrated with 5 column volumes (CV) of buffer A (10 mM Tris pH 8.5, 50 mM KCl, 112 
1 mM DTT). After loading of the soluble lysate the column was washed with 10 113 
CV (~200 ml) of buffer A and subsequently eluted with 20 CV in a linear gradient from 0% to 114 
25% of buffer B (10 mM Tris pH 8.5, 1 M KCl, 1 mM DTT). Loading, washing and 115 
elution were performed at a flow rate of 1 ml/min. Eluates were fractionated and 116 
examined by SDS-PAGE. PykA (pI 6.8) eluted in the range of 130-185 mM KCl 117 
and PykF (pI 6) eluted in the range of 160-200 mM KCl. The protein content of the fractions 118 
was analysed through SDS-PAGE and appropriate fractions were pooled and concentrated 119 
prior to gel filtration 120 
using polyethersulfone (PES) membranes (Sartorius Stedim Biotech, Vivaspin 20) with a 121 
molecular weight cut-off of 30 kD. 122 
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Size exclusion chromatography: A HiLoad 26/60 Superdex 200 prep grade 123 
column (GE Healthcare) equilibrated with buffer C (10 mM Tris pH 8, 100 124 
mM KCl, 1 mM DTT) was loaded with the concentrated protein (maximum volume of 125 
12.5 mL). The elution was carried out with the same buffer applying one CV (~330 ml) at a 126 
flow rate of 2 ml/min. The fractions were analysed by SDS-PAGE, pooled accordingly and 127 
concentrated. PykA (51.5 kDa) eluted with a maximum at 177 ml, whereas 128 
PykF (50.5 kDa) eluted slightly earlier with a maximum at 171 ml. The Superdex 200 prep 129 
grade column was calibrated with protein standards purchased from Sigma (Germany) to 130 
estimate molecular masses of PK complexes.  131 
 132 
Pyruvate kinase (PK) activity assay 133 
 134 
To measure PK activity, the reaction catalysed by PK was coupled with the lactate 135 
dehydrogenase (LDH) reaction. While LDH converts pyruvate to lactate it oxidises NADH to 136 
NAD+. The concentration of the latter was then measured at 340 nm [16]. The reaction 137 
mixture consisted of 50 mM Tris pH 7.5, 100 mM KCl, 10 mM MgCl2, 2.5 mM NADH, 2.4 138 
U LDH , 2 mM ADP, 5 mM PEP, and 100 nM of PykA and PykF, respectively. Reaction 139 
mixtures without PEP were pre-incubated for 5 min at 30°C, then reactions were started by 140 
addition of PEP. Reactions of 100 µl were recorded for 1 minute at 30°C with a Specord 50 141 
photometer (Analytik Jena, Germany) and the slopes of triplicates were averaged for 142 
calculation of NADH oxidation and PK activity, respectively. One unit of PK activity 143 
corresponds to 1 µmol of oxidized NADH per minute. 144 
 145 
Protein quantitation 146 
 147 
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Protein concentrations were determined applying the modified Bradford assay 148 
purchased from Bio-Rad (Germany) and using BSA as a standard. Protein gels were analyzed 149 
using the ImageJ software package.  150 
 151 
Circular dichroism (CD) spectroscopy 152 
 153 
CD data were acquired on a Jasco J-815 CD spectrometer (Jasco, Inc). PykA (22 μM), 154 
PykF (10 μM), and PykF in the presence of fructose-1,6-bisphosphate (FBP) (10 mM) were 155 
equilibrated in 20mM Tris-HCl (pH 8.0) and measured at 10 °C in 0.1-cm path length cuvette. 156 
Spectra were recorded in the 190-260 nm wavelength range with 1 nm increments (20 nm / 157 
min), 10 s averaging time, and 1 nm bandwidth for 10 repeats. The mean residue molar 158 
ellipticity was calculated by  159 
[ ] nlCM ××××Θ=Θ 100  160 
where Ө is the ellipticity in degrees, l the optical path in cm, C the protein concentration in 161 
mg/ml, M is the protein’s molecular mass, n the number of residues in the protein, and [Ө] the 162 
mean residue molar ellipticity in deg•cm2•dmol-1. The baseline-corrected spectra were used 163 
for protein secondary structure analysis. 164 
 165 
Small angle X-ray scattering (SAXS) 166 
 167 
The synchrotron radiation X-ray scattering data were collected following standard 168 
procedures on the X33 SAXS camera of the EMBL Hamburg located on a bending magnet 169 
(sector D) on the storage ring DORIS III of the Deutsches Elektronen Synchrotron (DESY) 170 
[17, 18]. As detector, a single photon counting pixel detector (PILATUS 1M, Dectris, 171 
Villingen, Switzerland) was used. A sample - detector distance of 3400 mm was used, 172 
covering the range of momentum transfer 0.11 < s < 2.8 nm-1 (s = 4π sin(θ)/λ, where θ is the 173 
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scattering angle and λ = 0.1504 nm is the X-ray wavelength) [18]. The S-axis was calibrated 174 
by the scattering pattern of Silver-behenate salt (d-spacing 5.84 nm). The protein solutions 175 
were automatically loaded to the vacuum sample chamber by a liquid handling sample 176 
changer robot [18, 19]. The scattering patterns from PykA, PykF, and PykF with FBP were 177 
measured at different protein concentrations in order to check for interparticle interferences. 178 
Protein samples were prepared in 10 mM Tris pH 8, 100 mM KCl and 1 mM DTT as radical 179 
quencher. Repetitive measurements of 15 sec at 10 °C of the same protein solution were 180 
performed in order to check for radiation damage. Stable intensities especially at low angles 181 
indicated that no protein aggregation took place during the exposure times. The data were 182 
normalized to the intensity of the incident beam; the scattering of the buffer was subtracted 183 
and the difference curves were scaled for concentration. All the data processing steps were 184 
performed using the program package PRIMUS [20]. The forward scattering I(0) and the 185 
radius of gyration Rg were evaluated using the Guinier approximation [21] assuming that for 186 
spherical particles at very small angles (s < 1.3/Rg) the intensity is represented by I(s) = I(0) 187 
exp(-(sRg)2/3). These parameters were also computed from the entire scattering patterns using 188 
the indirect transform package GNOM [22], which also provide the distance distribution 189 
function p(r) of the particle as defined:  190 
( )dssrsrsIrp ∫= sin)(2)( π  191 
The molecular masses of PykA, PykF and PykF with FBP were calculated by comparison 192 
with the forward scattering from the reference solution of bovine serum albumin (BSA). From 193 
this procedure a relative calibration factor for the molecular mass (MM) can be calculated 194 
using the known molecular mass of BSA (66 kDa) and the concentration of the reference 195 
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where I(0)p, I(0)st are the scattering intensities at zero angle of the studied and the BSA 198 
standard protein, respectively, MMp, MMst are the corresponding molecular masses and cp, cst 199 
are the concentrations. Errors on molecular weights have been calculated from the upper and 200 
the lower I(0) error  limit estimated by the Guinier approximation. 201 
Low-resolution models of PykA, PykF, and PykF with FBP were built by the program 202 
DAMMIN [23], which represents the protein as an assembly of dummy atoms inside a search 203 
volume defined by a sphere of the diameter Dmax. Starting from a random model, DAMMIN 204 
employs simulated annealing to build a scattering equivalent model fitting the experimental 205 
data Iexp(s) to minimize discrepancy: 206 



















χ  207 
 208 
where N is the number of experimental points, c a scaling factor and Icalc(sj) and σ(sj) are the 209 
calculated intensity and the experimental error at the momentum transfer sj, respectively. Ab 210 
initio shape models for PykA, PykF and PykF with FBP respectively were obtained by 211 
superposition of 20 independent DAMMIN reconstructions for each subunit by using the 212 
program packages DAMAVER [23] and SUBCOMP [23]. 213 
 214 
Results and discussion 215 
 216 
To recombinantly produce Yersinia enterocolitica pyruvate kinases PykA and PykF in 217 
their outright form without any tag, pykA and pykF coding regions were amplified by PCR 218 
and cloned into IPTG-inducible expression vector pWS [15]. Using BL21 pLysS as 219 
expression host, solubility of both PykA and PykF was superior when expression cultures 220 
were incubated at 27°C compared to 37°C, so that for large-scale production both proteins 221 
were expressed at 27°C after induction for 5 hours. In an analogous manner, both proteins 222 
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were purified from 400 ml of expression culture, applying ion exchange chromatography on a 223 
HiPrep 16/10 Q XL column and a subsequent size exclusion chromatography step on a 224 
Superdex 200 prep grade column. The purification of PykA and PykF is summarized in 225 
Tables 1 and 2 and illustrated by Figure 1, showing representative samples of both 226 
purification procedures analysed on Coomassie-stained gels after SDS-PAGE. The yield was 227 
approx. 100 and 73 mg of PykA and PykF, respectively, per 400 ml of expression culture 228 
corresponding to 250 and 183 mg/L. To the best of our knowledge, this is superior to any 229 
other reported PK expression and purification protocol (see Table 3). The specific activities 230 
determined for purified Y. enterocolitica PykA and PykF (85 and 108 U/mg) are in good 231 
agreement with values determined for other bacterial PK enzymes [24] (see Table 3). Elution 232 
of PykA and PykF from preparative size exclusion chromatography was in accordance with 233 
formation of tetramers (data not shown). Interestingly PykF (calculated monomeric mass of 234 
50.5 kDa) eluted significantly and reproducibly before PykA (51.5 kDa) with a peak 235 
maximum at 171 mL for PykF compared to 177 mL for PykA (data not shown). This could be 236 
explained by an unspecific interaction of PykA with the gel matrix delaying elution. 237 
Alternatively, a significant difference in the conformation of the PykA and the PykF tetramers 238 
such as induced by stable binding of a low molecular weight ligand (e.g. an allosteric effector) 239 
could be the reason for this phenomenon. The CD spectra (Fig. 2) exhibited two minima 240 
around 208 nm and 222 nm, which is a typical indication of α-helix conformation. Recorded 241 
CD spectra illustrate considerable structural differences between PykA and PykF and confirm 242 
their overall high content of α-helices. In the presence of the known allosteric activator 243 
fructose-1,6-bisphosphate (FBP) the CD spectrum of PykF was only marginally changed.   244 
To confirm the tetrameric organization of the purified isoenzymes, small angle X-ray 245 
scattering (SAXS) was applied (Fig. 3; supplementary data 1). Both, PykA and PykF formed 246 
tetramers, which were distinct (Fig. 3A and B). This could explain their significantly differing 247 
elution behaviour on the Superdex 200 column. Furthermore, a conformational transition of 248 
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the PykF tetramer could be observed upon addition of the allosteric effector fructose-1,6-249 
bisphosphate (FBP) (Fig. 3B and C). The allosteric activation of PykF-like PK enzymes is 250 
well-known, but to our knowledge the conformational transition has never been demonstrated 251 
applying SAXS. No conformational transition of PykA in the presence of FBP could be 252 
observed (data not shown), which is in line with the lack of allosteric influence of FBP on 253 
PykA-like enzymes [24]. 254 
Interestingly, available crystal structure coordinates of E. coli PykF (PDB: 1pky), 255 
being 86% identical to Y. enterocolitica PykF, did not fit very well into the SAXS-based 256 
model (data not shown). This could indicate differences between solution structure and crystal 257 
packing, or, alternatively, this could indicate differences between the homologous enzymes of 258 
E. coli and Y. enterocolitica.  259 
Finally, it is worthwhile mentioning that initially we had expressed PykA and PykF as 260 
glutathione S-transferase (GST) fusion proteins using plasmid pGEX-4T3 and yielded high 261 
level expression and purification of GST-PykA and GST-PykF. However, we failed to cleave 262 
both fusion proteins efficiently using thrombin, possibly due to steric hindrance. 263 
Collectively, the high-level production of Y. enterocolitica PykA and PykF may pave 264 
the way for their structural and functional characterization. In addition, this study highlights 265 
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 358 
 Legends to illustrations 359 
 360 
Fig. 1: Expression and purification of PykA (A) and PykF (B). Coomassie-stained SDS-361 
PAGE loaded with samples as indicated. BL21 pWS, whole cell lysate of expression host 362 
with backbone plasmid pWS treated with 0.1 mM IPTG; whole cell lysate of BL21 pWS-363 
pykA and BL21 pWS-pykF, respectively, after induction with 0.1 mM IPTG; “soluble” and 364 
“insoluble” refer to soluble and insoluble fractions of the respective lysates after 365 
centrifugation; AIEC and GF represent pooled samples after anionic exchange 366 
chromatography and gel filtration chromatography, respectively.     367 
 368 
Fig. 2: Structural characterization of PykA and PykF by CD spectroscopy. The far-UV 369 
spectra of PykA (22 µM), PykF (10 µM) and PykF + FBP (PykF: 9 µM; FBP: 10 mM) were 370 
recorded in 20 mM Tris-HCl (pH 8.0) at temperature 10 °C using a path length of 1 mm.   371 
 372 
Fig. 3: SAXS-based low resolution structural models of PykA and PykF.  373 
A: PykA; B: PykF; C: PykF + FBP. 374 
 375 
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Table 1 376 
 Summary of purification of Yersinia enterocolitica PykA recombinantly produced in E. colia 377 
Purification step Total protein 
 [mg] 




Purification [fold] Purity [%] 
Soluble bacterial 
lysate 
321 112 15729 49 1 35 
HiPrep 16/10 Q 
XL 
128 109 11264 88 2.43 85 
HiLoad 26/60 
Superdex 200 
105 100 8925 85 2.71 95 
a From 400 ml of bacterial culture 378 
 379 
Table 2 380 
 Summary of purification of Yersinia enterocolitica PykF recombinantly produced in E. colia 381 
Purification step Total protein 
 [mg] 




Purification [fold] Purity [%] 
Soluble bacterial 
lysate 
275 124 9625 35 1 45 
HiPrep 16/10 Q 
XL 
98 88 9800 100 2 90 
HiLoad 26/60 
Superdex 200 
79 73 8532 108 2.1 93 
a From 400 ml of bacterial culture 382 
383 
 17 
Table 3 384 
 385 
Comparison of published protocols on recombinant production of bacterial pyruvate kinasesa 386 





Escherichia coli PykF 30 190 [25] 
Staphylococcus aureus PK 30-40  100 [24] 
Chlamydia trachomatis 6 55 [26] 
aOnly publications providing data on both yield and specific activity of recombinantly 387 
produced pyruvate kinases were included. 388 
Hofmann et al. 
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+    scattering intensity of PykF 
---  shape model calculation 
SAXS intensities of PykF in comparison with calculated shape model of PykF (Fig. 3). The chi value, describing the 
discrepancy of the experimental data to the shape model calculation is 1.1. The chi values for PykF+FBP and PykA (see Fig. 
3) are similar.  
Hofmann et al. 
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